Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
Official title: Androgen Receptor Action in Castration Resistant Prostate Cancer
Funded at Beth Israel Deaconess Medical Center · NIH-11419184 · Data updated 2026-11-12
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 24, 2013 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,644,070 |
| NIH project number | 5P01CA163227-12 |
| Project ID | NIH-11419184 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with castration-resistant prostate cancer or those whose disease has progressed after AR-targeted therapy, who could provide tumor tissue samples or participate in related studies.
✕Less likely to help
Patients whose cancer is not driven by AR signaling or who are not eligible for tissue donation may not benefit.
What this research studies
Researchers at Beth Israel Deaconess Medical Center will study how the androgen receptor keeps prostate cancer cells alive and dividing even after standard therapies. They will look for changes in the AR-related gene programs and identify new vulnerabilities that arise as the cancer becomes resistant. The work combines analyses of patient samples and cellular models to map how AR signaling shifts over time. The goal is to translate these findings into therapeutic strategies that can overcome resistance and improve patient outcomes.
Why it matters
Potential benefit: If successful, the research could lead to new treatments that prevent or overcome resistance to AR-targeted therapy in prostate cancer.
How similar studies have gone: Previous work supports AR as a key driver in resistant prostate cancer, with ongoing efforts showing promise in identifying resistance mechanisms and vulnerabilities.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Balk, Steven P. — Beth Israel Deaconess Medical Center
- Study coordinator: Balk, Steven P.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
-
Stopping therapy-resistant prostate cancer by blocking FOXA2 and AP-1
This research looks at whether blocking a protein switch called FOXA2 and its partner AP‑1 can stop or reverse prostate cancers that no longer respond to hormone therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.